Skip to main content
OpenTrials

Clinical trial condition

Lymphoma

Explore clinical trials studying Lymphoma. Study availability and eligibility vary by location and protocol.

3,646 public trials 848 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma trial results

Active, Not Recruiting

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

NCT02879695

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +22 more
Locations
  • Yale University New Haven, Connecticut, United States
  • University of Kentucky/Markey Cancer Center Lexington, Kentucky, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Active, Not Recruiting

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT04077723

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations
  • City of Hope Medical Center Pasadena, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
View all 35 locations
View Trial Details
Active, Not Recruiting

Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

NCT03016871

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +8 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Yale University New Haven, Connecticut, United States
  • M D Anderson Cancer Center Houston, Texas, United States
  • Fred Hutchinson Cancer Research Center Seattle, Washington, United States
View Trial Details
Active, Not Recruiting

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

NCT01840566

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations
  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack (Limited protocol activities) Commack, New York, United States
View Trial Details
Active, Not Recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT02568267

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Adnexal Diseases, +91 more
Locations
  • Dignity Health St Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • Mayo Clinic Phoenix, Arizona, United States
  • City of Hope Cancer Center Duarte, California, United States
  • City of Hope Duarte - Comprehensive Cancer Center, Investigational Drug Services Duarte, California, United States
View all 130 locations
View Trial Details
Active, Not Recruiting

Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma

NCT02159755

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Washington University School of Medicine St Louis, Missouri, United States
  • NYP/Weill Cornell Medical Center New York, United States
  • UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
View Trial Details
Active, Not Recruiting

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

NCT03598998

Conditions
Anaplastic Large Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Hemic and Lymphatic Diseases, +35 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • University of Nebraska Medical Center Omaha, Nebraska, United States
View Trial Details

Related conditions